EU focuses on safety and effectiveness of pandemic vaccines
This article was originally published in SRA
Executive Summary
As vaccination campaigns against pandemic flu get underway, the European regulatory and health authorities have laid out their strategy for monitoring the benefit:risk profiles of the various vaccines. The emphasis will be on the rapid detection and reporting of major safety issues such as life-threatening reactions and birth defects, as well as on the effectiveness and immunogenicity of the individual vaccines.
You may also be interested in...
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.
EU Countries Offered Funding To Contribute to African Regulatory Strengthening
Training projects are intended to strengthen the African regulatory environment, boost the capacity of the African Medicines Agency, facilitate regulatory reliance, and increase joint new drug assessments.